- Frost & Sullivan to Host Quarterly Analyst Briefing on the European Cardiac Rhythm Management Market on Wednesday 25 February 2009
—
LONDON, February 16LONDON, February 16 /PRNewswire/ -- The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European Cardiac Rhythm Management Market to be held on Wednesday, 25 February, 2009 at 4 p.m. GMT.
(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)
Cardiovascular disease (CVD) is the leading cause of premature death on a global scale and is projected to remain so in the near future. CVD encompasses coronary artery disease, hypertension, heart failure and cardiomyopathy. The mechanical failure of the heart due to CVD affects the conduction system of the heart. Depending on the level of malfunction, the manifestation of outcome varies from angina pectoris to ventricular arrhythmia.
Demographics such as the increasing baby-boomer population, sedentary lifestyle, and increased disorders such as obesity, diabetes, smoking and others often result in cardiovascular ailments like for example arrhythmia, congestive heart failure, cardiomyopathy, and atherosclerosis. Rising awareness for such ailments and potentially increasing diagnostics help to attract interest of the target population.
At the same time, the Western European industry for Cardiac Rhythm Management is facing a high degree of consolidation, which has led to strenuous competition. The major participants in the market try to acquire the smaller ones, making it difficult for the niche participants to survive. Brand loyalty of devices forms an additional factor that creates a hostile platform for new players entering the market, because customers are often loyal to their chosen brand which reflects in their repurchase behaviour.
Collaborative partnerships, together with technological innovations and scalability will therefore determine the future of this market.
Highlights of the Frost & Sullivan briefing include analyses of R&D investment, challenges and drivers of the Cardiac Rhythm Management Market, and reasons for stakeholders to invest in the medical device industry. The briefing will benefit medical device manufacturers, distributors and cardiologists.
"Despite the global economic meltdown, the Cardiac Rhythm Management industry has survived the tough weather owing to its pocket being deep enough to wield over," concludes SreeVidhya Praveenkumar, Research Associate from Frost & Sullivan.
Frost & Sullivan will hold this conference call at 4 p.m. GMT on Wednesday, 25 February, 2009, which will provide industry participants an outlook of the European Cardiac Rhythm Management Market. To participate, please email Katja Feick at katja.feick@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. Upon receipt of the above information, a registration link will be emailed to you.
Frost & Sullivan has expanded its flagship Global Congress on Corporate Growth - GIL Global - into several major cities around the world including London. For the first time ever in Europe, Frost & Sullivan will be hosting the Growth, Innovation and Leadership Congress 'GIL 2009: Europe' on 19-20 May, at the Sofitel St James in London. GIL Global is the industry's only event designed to support senior executives in their efforts to achieve sustainable, top-line growth. To register, obtain a programme agenda, explore sponsorship opportunities, or attend as a member of the media for GIL 2009: Europe, please contact Katja Feick, Corporate Communications Europe, at katja.feick@frost.com. One-on-One interviews with Frost & Sullivan senior growth consultants are also being scheduled. For more information you can also visit www.frost.com/giluk
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.
Contact: Katja Feick Corporate Communications - Europe P: +49-(0)-69-77-0-33-43 F: +49-(0)-69-23-45-66 E: katja.feick@frost.com www.frost.com
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
